CTA Treatment Regimen Chart for Esophageal and EGJ Cancers Updated
CTA has updated its treatment regimen chart for the treatment of esophageal and esophagogastric junction cancers.
Cancer Therapy Advisor has updated its treatment regimen chart for the treatment of esophageal and esophagogastric junction cancers to reflect the most recent changes put forth by Version 2.2016 of the National Comprehensive Cancer Network (NCCN) Guidelines for Esophageal and Esophagogastric Junction Cancers.
Key updates from Version 2.2016 and Version 1.2016 for the systemic treatment of metastatic or locally advanced esophageal and esophagogastric junction cancers include:
- DCF (docetaxel, cisplatin, and fluorouracil) (Category 1) was removed as a preferred treatment option as first-line therapy.
- ECF (epirubicin, cisplatin, and fluorouracil) (Category 1) and ECF modifications (Category 1) were removed from the list of preferred regimens for first-line therapy and added to the list of other regimens.
- Docetaxel and irinotecan was removed as an option for first-line therapy.
- Alternative regimens for consideration, including mitomycin plus irinotecan or fluorouracil, were removed.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Esophageal and Esophagogastric Junction Cancers. V 2.2016. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Updated July 7, 2016. Accessed September 20, 2016.